跳至主要内容
临床试验/NCT05910684
NCT05910684已完成不适用

Establishing Clinical Utility Evidence for Chronic Disease Management Testing: A CPV® and Chart Abstraction Randomized Controlled Trial

Qure Healthcare, LLC2 个研究点 分布在 1 个国家目标入组 114 人开始时间: 2022年7月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
114
试验地点
2
主要终点
Chart abstraction measured variation in quantity of care

研究概览

简要总结

This is a national-level research study of primary care physicians. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling, and others) of a subset of common patient care indications.

详细描述

In the original study protocol (approved on October 19th, 2021), which the investigators are now referring to as Phase 1, the investigators measured changes in clinical practice using Clinical Performance and Value (CPVs) vignettes, described below. Phase 1 utilized simulated patients to determine clinical variation in the management of chronic cardiometabolic diseases and assessed the impact of the CDMT results on physicians' clinical decision-making.

CPVs are QURE's scientifically-validated measurement tool, first described in JAMA, 2000, and now used in scores of scientific investigations. In this research and derivative peer-reviewed publications, QURE's CPV studies efficiently measure clinical practice patterns among active physicians to determine if there is value in new technologies to payers.

This amendment allows us to ask the same physicians if they change their practice in an actual clinical setting.

Phase 2 extends the findings from Phase 1 by measuring the change in clinical practice using CPVs and securing data on practice patterns from abstracted medical records. the investigators will look for the same changes the investigators found in Phase 1 to determine the impact of CDMT on real-world clinical decisions and patient outcomes. The advantage of Phase 2 is that it leverages the same sample frame and the randomization by returning to the physicians in Round 1 who indicated that CDMT would change their practice. These physicians will be given, free of charge, the option of using CDMT on their real patients who share similar medical diagnoses as the CPV simulated patients. Phase 2 will thus provide patient-level data on the impact of medication adherence assessment on quality outcomes including, but not limited to, blood pressure control, blood sugar control, and parameters of disease progression

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Board-certified physician currently practicing in either Family Medicine or Internal Medicine.
  • Have practiced as a board-certified physician in internal or family medicine or greater than 2 but less than 30 years
  • Community/non-academic based practice setting
  • ≥ 40 patients under care weekly
  • Commonly treats patients with atrial fibrillation, coronary artery disease, congestive heart failure, diabetes, hypertension, and hyperlipidemia
  • Patient HIPAA Authorization form signed upon initial enrollment into the provider's practice
  • Practicing in the U.S.
  • English-speaking
  • Access to the internet
  • Informed and voluntarily consented to be in the study

排除标准

  • Not a board-certified physician
  • Not practicing in the United States
  • Not informed and voluntarily consented to be in the study.

结局指标

主要结局

Chart abstraction measured variation in quantity of care

时间窗: [19 months]

Measuring the difference in the quality of care between the control arm and the intervention arm as measured by the number of care decisions made in the second round of chart abstraction. These care decisions might include decisions such as avoidance of invasive diagnostic tests, reductions in unneeded specialist referrals, increased diagnosis and treatment of drug-drug interactions, or care decisions related to costs.

Chart abstraction measured variation in quality of care

时间窗: [19 months]

Measuring the difference in the quality of care between the control arm and the intervention arm as measured by the quality of care decisions made in the second round of chart abstraction. These care decisions might include decisions such as avoidance of invasive diagnostic tests, reductions in unneeded specialist referrals, increased diagnosis and treatment of drug-drug interactions, or care decisions related to costs.

Chart abstraction measured variation in clinical decisions

时间窗: [19 months]

Measuring the variation in amount of evidence based clinical decisions among practicing primary care physicians in the assessment, recognition, and adjustment of treatment due to medication non-adherence and DDIs in patients with chronic cardiometabolic diseases.

次要结局

未报告次要终点

研究者

发起方
Qure Healthcare, LLC
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验